Editor's Note: This article has been updated to clarify Michael's position. Novartis may give away its $475,000 cancer drug Kymriah to low-income patients who either don’t have insurance or have been denied access to the CAR T therapy by their insurer, according to an HHS Inspector General advisory opinion . Although specific to Novartis’ Kymriah, the opinion could be a model for makers of other chimeric antigen receptor T-cell treatments, according to Epstein Becker Green Partner Jennifer...